Takeda Pharmaceuticals U.S.A. Inc.
1 Takeda Pkwy
About Takeda Pharmaceutical
Millennium Pharmaceuticals was established in 1993 as a genomics company, applying world-class molecular biology and genomic technologies to the discovery and development of new therapies in a broad spectrum of diseases. Over time we evolved into a fully integrated biopharmaceutical company.
In May 2008, Millennium was acquired by Takeda Pharmaceutical Company Limited in Japan and became known as Millennium: The Takeda Oncology Company (Millennium), a wholly-owned subsidiary of Takeda that served as the organization’s global center of excellence in oncology.
The combination of oncology resources resulted in a robust pipeline that addresses a broad range of cancers. Our focus is to improve the treatment of cancer, which gives us an important oncology mission to deliver extraordinary medicines to patients with cancer worldwide through our science, innovation and passion, toward an ultimate goal and aspiration to cure cancer.
In May 2013, the decision was made to fully integrate Millennium into the global Takeda R&D engine to maximize the resources available from the broader Takeda organization and to realize greater operational efficiencies. The R&D and G&A functions in Boston became known publically as Takeda Pharmaceuticals International Co. The oncology Commercial, Business Development and Patient Advocacy divisions continue to operate as Millennium: The Takeda Oncology Company.
At Takeda and Millennium, we want to exceed expectations in terms of progress against cancer, distinguishing ourselves within the research-based biopharmaceutical community. We’re prepared to deliver on this goal by focusing on novel or best-in-class drug candidates, and cultivating the brightest talent. This puts Takeda on an exciting path toward global oncology leadership.
We help drive and accelerate the progress that continually is being made against cancer; these advances, sometimes big breakthroughs and sometimes incremental, make a real difference in the lives of patients. We won’t be satisfied until cures are found and the threat is removed. People who battle cancer deserve no less.
Our goal also is to provide patients and people close to them with easily understandable information about the diseases our products treat, as well as other relevant information and service resources. We also provide information about our investigational drugs that are approaching or in development, our clinical trials, and what patients, caregivers and healthcare providers need to know about our assistance and access programs for any drug we currently market. We work toward our goals with the same urgency for patients that we would for our families. We strive to earn the respect and admiration of the global oncology community by delivering significant progress against cancer while living our core values.
The people and culture at Takeda and Millennium make all the difference.
Our work is more than a job. We are entrepreneurial about both our work and achieving progress. We focus on what’s important and timely decision-making.
As a site based in New England, we enjoy our local community and contribute in many ways to local business, social and environmental causes. We offer a broad range of opportunities for campus-based employees to participate. We also involve ourselves on a corporate level in matters of social responsibility.
June 12, 1781
Founder: Chobei Takeda
CEO: Christophe Weber
CMO (Medical) and CSO (Scientific): Andrew Plump
CFO: James Kehoe
Please click here for Takeda job opportunities.
Tweets by Takeda
1026 articles with Takeda Pharmaceutical
Sosei Heptares and Takeda Enter Into New Strategic Multi-target Research, Development and Commercialization Partnership
Collaboration combines Sosei Heptares' GPCR-focused StaR® and structure-based drug design capabilities with Takeda's discovery, development and therapeutic area expertise
Sosei Group Corporation inked a strategic multi-target partnership with Takeda Pharmaceutical to find, develop and commercialize small molecules and biologics that modulate G protein-coupled receptor targets. The initial focus will be on gastrointestinal targets.
Revenue 849.1 billion yen, up +88.8% versus prior year mainly due to acquisition of Shire, with solid performance of 14 global growth brands
Takeda Announces FY2019 Key Performance IndicatorsAligned with Shareholder Value Creation and Focused on Successful Integration
Takeda Pharmaceutical Company Limited announces that the Takeda Board of Directors has approved key performance indicators to be included in both the company’s short-term and long-term incentive plans for fiscal year 2019, as well as a Special Integration plan designed to promote the successful integration of Shire.
7/29/2019A number of companies reported clinical trial data last week. Here’s a look.
PRA Health Sciences, Inc. Expands Service Provisions to Pharmaceutical and Biotech Companies Through Buyout of Takeda Joint Venture in Japan
PRA Health Sciences, Inc. (NASDAQ: PRAH, “PRA”) announced the buyout of its joint venture with Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) in Japan, which was completed on June 1.
Crescendo Biologics Ltd announces that Takeda Pharmaceutical Company Limited, has exercised a second option under its existing, multi-target collaboration and license agreement.
Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease
Vedolizumab subcutaneous is currently under review for approval for ulcerative colitis with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA)
Takeda will release complete Phase III data at a future scientific conference and is planning on seeking regulatory approval for the investigational formulation.
In May, the company sold off assets worth $5.7 billion and now, the company is looking to sell more.
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
Four years ago, Takeda Pharmaceutical Company and The Center for iPS Cell Research and Application (CiRA) at Kyoto University established a 10-year joint research program. Today, the organizations made an announcement.
Takeda Pharmaceutical Company Limited announced that it has been selected for the 15th consecutive year by the FTSE4Good Developed Index, one of the world’s premier indices for Socially Responsible Investment (SRI), created by FTSE Russell.* In addition, Takeda was named to the MSCI ESG Leaders Index for the 10th consecutive year.
Takeda Unveil New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalized Prophylaxis with ADYNOVATE in Severe Hemophilia A
Takeda Pharmaceutical Company Limited, R&D-driven, global biopharmaceutical company with a leadership position in rare diseases, has announced updated results from its phase IIIb/IV clinical trial for ADYNOVATE® [Antihemophilic Factor, PEGylated] at the 27th Annual International Society on Thrombosis and Haemostasis Congress, in Melbourne, Australia.
48 presentations and sessions to showcase Takeda’s hematology gene therapy pipeline and leading factor portfolio
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone payments.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK
Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program, Supporting Disease Prevention to Improve Health in Developing and Emerging Countries
Takeda’s founding mission to serve patients, wherever they are, drives its increased commitments to disease prevention, capacity building, and access to healthcare in developing and emerging countries, in partnership with the global community.
Takeda Pharmaceutical Company Limited hereby announces that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2019 with the U.S. Securities and Exchange Commission.
OrbiMed Comments on Takeda Pharmaceutical Company Limited Proxy Ahead of 143rd Ordinary General Meeting of Shareholders 2019
OrbiMed Advisors LLC has evaluated the proxy voting recommendations from both Institutional Shareholder Services Inc. and the management of Takeda Pharmaceutical Company Ltd. ahead of the 143rd Ordinary General Meeting of Shareholders that will take place on June 27, 2019, in Yokohama, Japan.